CN114181893B - 肝脏双表型细胞的成熟方法 - Google Patents
肝脏双表型细胞的成熟方法 Download PDFInfo
- Publication number
- CN114181893B CN114181893B CN202210119890.2A CN202210119890A CN114181893B CN 114181893 B CN114181893 B CN 114181893B CN 202210119890 A CN202210119890 A CN 202210119890A CN 114181893 B CN114181893 B CN 114181893B
- Authority
- CN
- China
- Prior art keywords
- liver
- cells
- culture medium
- medium
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004185 liver Anatomy 0.000 title claims abstract description 95
- 238000000034 method Methods 0.000 title claims abstract description 27
- 210000004027 cell Anatomy 0.000 claims abstract description 101
- 230000035800 maturation Effects 0.000 claims abstract description 47
- 210000005229 liver cell Anatomy 0.000 claims abstract description 14
- 239000002243 precursor Substances 0.000 claims abstract description 13
- 239000001963 growth medium Substances 0.000 claims description 50
- 210000002220 organoid Anatomy 0.000 claims description 48
- 210000003494 hepatocyte Anatomy 0.000 claims description 27
- 239000002609 medium Substances 0.000 claims description 27
- 239000000654 additive Substances 0.000 claims description 19
- 230000000996 additive effect Effects 0.000 claims description 19
- 239000012190 activator Substances 0.000 claims description 18
- 239000003112 inhibitor Substances 0.000 claims description 18
- 230000002440 hepatic effect Effects 0.000 claims description 13
- 108010082117 matrigel Proteins 0.000 claims description 11
- 102000000344 Sirtuin 1 Human genes 0.000 claims description 9
- 108010041191 Sirtuin 1 Proteins 0.000 claims description 9
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 9
- DVKQVRZMKBDMDH-UUOKFMHZSA-N 8-Br-cAMP Chemical group C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Br DVKQVRZMKBDMDH-UUOKFMHZSA-N 0.000 claims description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 7
- 239000007640 basal medium Substances 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 3
- 102000038379 digestive enzymes Human genes 0.000 claims description 3
- 108091007734 digestive enzymes Proteins 0.000 claims description 3
- 230000003203 everyday effect Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 claims 6
- 102000004140 Oncostatin M Human genes 0.000 claims 3
- 108090000630 Oncostatin M Proteins 0.000 claims 3
- 229960003957 dexamethasone Drugs 0.000 claims 3
- 239000003623 enhancer Substances 0.000 claims 3
- 239000003969 proliferation enhancer Substances 0.000 claims 3
- 235000012711 vitamin K3 Nutrition 0.000 claims 3
- 239000011652 vitamin K3 Substances 0.000 claims 3
- 229940041603 vitamin k 3 Drugs 0.000 claims 3
- 210000000056 organ Anatomy 0.000 abstract description 6
- 238000000338 in vitro Methods 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 230000004069 differentiation Effects 0.000 abstract description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 abstract description 2
- 239000000306 component Substances 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 102100027211 Albumin Human genes 0.000 description 11
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 10
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- WAOBCCBUTHNTFO-UHFFFAOYSA-N 2-(5-chloro-2-methyl-n-methylsulfonylanilino)-n-(2,6-difluorophenyl)acetamide Chemical compound CC1=CC=C(Cl)C=C1N(S(C)(=O)=O)CC(=O)NC1=C(F)C=CC=C1F WAOBCCBUTHNTFO-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000005138 cryopreservation Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 3
- 108010020070 Cytochrome P-450 CYP2B6 Proteins 0.000 description 3
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 3
- 102100038739 Cytochrome P450 2B6 Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 2
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 2
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101000711846 Homo sapiens Transcription factor SOX-9 Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 102100034204 Transcription factor SOX-9 Human genes 0.000 description 2
- 108010076089 accutase Proteins 0.000 description 2
- 230000011748 cell maturation Effects 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000002372 intrahepatic bile duct epithelial cell Anatomy 0.000 description 2
- 229960000381 omeprazole Drugs 0.000 description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
- 229960002695 phenobarbital Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 208000005038 Cytochrome P-450 CYP1A2 Inducers Diseases 0.000 description 1
- 208000004836 Cytochrome P-450 CYP2B6 Inducers Diseases 0.000 description 1
- 208000000130 Cytochrome P-450 CYP3A Inducers Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010072268 Drug-induced liver injury Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 102100022054 Hepatocyte nuclear factor 4-alpha Human genes 0.000 description 1
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101001045740 Homo sapiens Hepatocyte nuclear factor 4-alpha Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 101710123134 Ice-binding protein Proteins 0.000 description 1
- 101710082837 Ice-structuring protein Proteins 0.000 description 1
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 1
- 101100096242 Mus musculus Sox9 gene Proteins 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 238000001190 Q-PCR Methods 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102220608300 Transcription factor SOX-2_H15Y_mutation Human genes 0.000 description 1
- 101710107540 Type-2 ice-structuring protein Proteins 0.000 description 1
- 238000008083 Urea Assay Methods 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000012 chronic liver injury Toxicity 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000005206 flow analysis Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003651 pro-proliferative effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
- C12N5/0672—Stem cells; Progenitor cells; Precursor cells; Oval cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/237—Oncostatin M [OSM]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
试剂名称 | 公司(货号) |
TrypLE | Gibco (12605010) |
Accutase | Sigma (A6964) |
STEM-CELLBANKER (DMSO-free) | AMSBIO (11890F) |
DMEM/F12 | Gibco (11039021) |
Ad-F12 | Gibco (12634028) |
William's E | Gibco (A1217601) |
HepatoZYME | Gibco (17705021) |
HCM | Lonza (CC-3198) |
KSR | Gibco (10828028) |
B27 | Gibco (17504044) |
ITS+3 | Sigma (I2771) |
A83-01 | Sigma (SML0788) |
NIC | Sigma (N0636) |
rhEGF | R&D (236-EG) |
rhFGF10 | R&D (345-FG) |
rhHGF | R&D (294-HG) |
rhRSPO1 | R&D (4645-RS) |
FH1 | Sigma (SML0826) |
FPH1 | Sigma (SML0827) |
MK4 | Sigma (V9378) |
rhOSM | R&D (295-OM) |
FBS | BI (04-001-1A) |
MK125 | Sigma (D4902) |
Matrigel | Corning (354277) |
Matrigel (GFR) | Corning (356230) |
Trizol | Invitrogen (15596018) |
Evo M-MLV RT Kit with gDNA Clean for qPCR | AG (AG11705) |
SYBR Green Premix Pro Taq HS qPCR Kit | AG (AG11718) |
Human liver RNA | Clontech (636531) |
Inducing cryopreserved male Human Hepatocyte | H1000.H15C+ |
DMSO | Sigma (D2650) |
RIF | Sigma (R3501) |
OMEP | Sigma (19329) |
PB | Cayman (9001494) |
P450-Glo™ CYP3A4 Assay | Promega (V9002) |
P450-Glo™ CYP2C9 Assay | Promega (V8791) |
P450-Glo™ CYP1C2 Assay | Promega (V8771) |
CellTiter-Glo® 3D Cell Viability Assay | Promega (G9683) |
Human primary hepatocyte | Lonza (HUCPI) |
Human Albumin Elisa Kit | Bethyl Laboratories (E88-129) |
QuantiChrom™ Urea Assay Kit | BioAssay Systems (DIUR-100) |
Normal Donkey Serum | Jacksonlab (017-000-121) |
DAPI | Sigma (D9542) |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210119890.2A CN114181893B (zh) | 2022-02-09 | 2022-02-09 | 肝脏双表型细胞的成熟方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210119890.2A CN114181893B (zh) | 2022-02-09 | 2022-02-09 | 肝脏双表型细胞的成熟方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114181893A CN114181893A (zh) | 2022-03-15 |
CN114181893B true CN114181893B (zh) | 2022-09-13 |
Family
ID=80545845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210119890.2A Active CN114181893B (zh) | 2022-02-09 | 2022-02-09 | 肝脏双表型细胞的成熟方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114181893B (zh) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014124527A1 (en) * | 2013-02-18 | 2014-08-21 | University Health Network | Methods for generating hepatocytes and cholangiocytes from pluripotent stem cells |
EP3307874A4 (en) * | 2015-06-12 | 2019-04-24 | Agency For Science, Technology And Research | DERIVATION OF HEPATIC STEM CELLS AND TYPES OF HEPATIC CELLS AND ASSOCIATED USES THEREOF |
CN111909887A (zh) * | 2019-05-10 | 2020-11-10 | 北京大学 | 获得肝脏细胞的方法和组合物 |
CN111004770B (zh) * | 2019-09-25 | 2022-08-23 | 中国人民解放军军事科学院军事医学研究院 | 功能性肝细胞诱导方法及其专用三维诱导培养基和应用 |
CN113388573B (zh) * | 2021-08-17 | 2021-11-19 | 天九再生医学(天津)科技有限公司 | 一种衍生自hPSC的肝脏双表型细胞构成的肝类器官获取方法 |
-
2022
- 2022-02-09 CN CN202210119890.2A patent/CN114181893B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN114181893A (zh) | 2022-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2956538B1 (en) | Bioengineered liver constructs and methods relating thereto | |
KR100832592B1 (ko) | 폴리머 막을 이용한 줄기세포와 피더세포의 공배양방법 | |
Xu et al. | Basic fibroblast growth factor supports undifferentiated human embryonic stem cell growth without conditioned medium | |
JP5777127B1 (ja) | 原始腸内胚葉細胞及びその作製方法 | |
EP2277993B1 (en) | Method for producing endothelial cells (variants) | |
EP2273996B1 (en) | Human cardiovascular progenitor cells | |
US11920160B2 (en) | Pancreatic insulin-producing beta-cell lines derived from human pluripotent stem cells | |
US20080182328A1 (en) | Mammalian extraembryonic endoderm cells and methods of isolation | |
US20100062527A1 (en) | Induction, propagation and isolation of liver progenitor cells | |
KR20070001101A (ko) | 포유동물의 골수 세포 또는 제대혈 유래 세포와 지방조직을 이용한 심근 세포의 유도 | |
EP2495320A1 (en) | Method for induction of differentiation of stem cells into hepatocytes | |
KR101918817B1 (ko) | 인간 줄기세포 유래 간세포 분화 방법 및 간세포 | |
CN110809625A (zh) | 用于获得类器官的组合物和方法 | |
CN100523213C (zh) | 产生灵长类动物滋养层的方法 | |
CN108865969B (zh) | Mapk/pkc信号通路激活剂促进人类胆管细胞分化和成熟 | |
US7332336B2 (en) | Methods for inducing differentiation of pluripotent cells | |
WO2004104184A1 (ja) | 内胚葉系幹細胞の調製 | |
CN101684454B (zh) | 一种定型内胚层细胞的制备和分离方法 | |
JP2022549882A (ja) | 肺細胞増殖および分化のためのシステムおよび方法 | |
EP3747991A1 (en) | Cell induction method | |
CN114181893B (zh) | 肝脏双表型细胞的成熟方法 | |
CN114149961B (zh) | 一种多谱系肝脏类器官及其构建方法和应用 | |
CN113151147B (zh) | 功能性肝实质细胞及其制备方法 | |
Yoshida et al. | Analysis of gene expressions of embryonic stem‐derived Pdx1‐expressing cells: Implications of genes involved in pancreas differentiation | |
CN115975913B (zh) | 一种利用多能干细胞诱导分化胆囊祖细胞的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220823 Address after: Room 906, Building 22, Green Valley Health Industrial Park, No. 59, Kangtai Avenue, Binhai Science and Technology Park, High-tech Zone, Binhai New District, Tianjin 300452 Applicant after: Tianjin exosome Technology Co.,Ltd. Address before: 300452 building 20, Green Valley Health Industrial Park, No. 59, Kangtai Avenue, Binhai Science Park, high tech Zone, Binhai New Area, Tianjin Applicant before: Tianjiu regenerative medicine (Tianjin) Technology Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240229 Address after: Room 915-30, 9th Floor, Zhongxin Ecological Building, No. 2 Keying Road, Suzhou Industrial Park, Suzhou City, Jiangsu Province, 215000 Patentee after: Qijia Technology (Suzhou) Co.,Ltd. Country or region after: China Address before: Room 906, Building 22, Green Valley Health Industrial Park, No. 59, Kangtai Avenue, Binhai Science and Technology Park, High-tech Zone, Binhai New District, Tianjin 300452 Patentee before: Tianjin exosome Technology Co.,Ltd. Country or region before: China |